Cargando…
Healthcare Cost Development in a Type 2 Diabetes Patient Population on Glucose-Lowering Drug Treatment: A Nationwide Observational Study 2006–2014
OBJECTIVE: The objective of this study was to describe healthcare resource use and cost development in Sweden during 2006–2014 in a type 2 diabetes (T2D) population receiving glucose-lowering drugs (GLDs). METHODS: In- and outpatient healthcare resource use and costs were extracted from mandatory na...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6249189/ https://www.ncbi.nlm.nih.gov/pubmed/29623637 http://dx.doi.org/10.1007/s41669-017-0063-y |
_version_ | 1783372689202741248 |
---|---|
author | Nathanson, David Sabale, Ugne Eriksson, Jan W. Nyström, Thomas Norhammar, Anna Olsson, Urban Bodegård, Johan |
author_facet | Nathanson, David Sabale, Ugne Eriksson, Jan W. Nyström, Thomas Norhammar, Anna Olsson, Urban Bodegård, Johan |
author_sort | Nathanson, David |
collection | PubMed |
description | OBJECTIVE: The objective of this study was to describe healthcare resource use and cost development in Sweden during 2006–2014 in a type 2 diabetes (T2D) population receiving glucose-lowering drugs (GLDs). METHODS: In- and outpatient healthcare resource use and costs were extracted from mandatory national registries: the Cause of Death Register; the National Patient Register; and the Prescribed Drug Register. Primary care data were estimated based on an observational study including patients from 84 primary care centers in Sweden. Numbers of any cause inpatient, outpatient, and primary care contacts were extracted and direct healthcare costs were estimated. RESULTS: During 2006–2014, the number of inpatient and primary care contacts increased by approximately 70% (from 45,559 to 78,245 and from 4.9 to 8.8 million, respectively) and outpatient care contacts almost doubled (from 105,653 to 209,417). Mean annual per patient costs increased by 13%, reaching €4594. Total healthcare costs increased from €835 million to €1.684 billion. Inpatient care costs constituted 47% of total costs in 2014 (€783 million), primary care accounted for 24% (€405 million), outpatient care 18% (€303 million), non-GLD medications 6% (€109 million), and GLDs 5% (€84 million). Cardiovascular diseases (CVDs) were the most costly disease group in inpatient care (26%), whereas managing unspecified factors influencing health and T2D-associated diseases were the most costly in outpatient care (16 and 11%, respectively). CONCLUSIONS: The healthcare costs of the GLD-treated T2D population doubled during 2006–2014, mostly driven by the increasing size of this population, of which inpatient care accounted for 47%. GLDs constituted the smallest share of costs. CVD was the most resource-requiring disease group. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s41669-017-0063-y) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6249189 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-62491892018-12-06 Healthcare Cost Development in a Type 2 Diabetes Patient Population on Glucose-Lowering Drug Treatment: A Nationwide Observational Study 2006–2014 Nathanson, David Sabale, Ugne Eriksson, Jan W. Nyström, Thomas Norhammar, Anna Olsson, Urban Bodegård, Johan Pharmacoecon Open Original Research Article OBJECTIVE: The objective of this study was to describe healthcare resource use and cost development in Sweden during 2006–2014 in a type 2 diabetes (T2D) population receiving glucose-lowering drugs (GLDs). METHODS: In- and outpatient healthcare resource use and costs were extracted from mandatory national registries: the Cause of Death Register; the National Patient Register; and the Prescribed Drug Register. Primary care data were estimated based on an observational study including patients from 84 primary care centers in Sweden. Numbers of any cause inpatient, outpatient, and primary care contacts were extracted and direct healthcare costs were estimated. RESULTS: During 2006–2014, the number of inpatient and primary care contacts increased by approximately 70% (from 45,559 to 78,245 and from 4.9 to 8.8 million, respectively) and outpatient care contacts almost doubled (from 105,653 to 209,417). Mean annual per patient costs increased by 13%, reaching €4594. Total healthcare costs increased from €835 million to €1.684 billion. Inpatient care costs constituted 47% of total costs in 2014 (€783 million), primary care accounted for 24% (€405 million), outpatient care 18% (€303 million), non-GLD medications 6% (€109 million), and GLDs 5% (€84 million). Cardiovascular diseases (CVDs) were the most costly disease group in inpatient care (26%), whereas managing unspecified factors influencing health and T2D-associated diseases were the most costly in outpatient care (16 and 11%, respectively). CONCLUSIONS: The healthcare costs of the GLD-treated T2D population doubled during 2006–2014, mostly driven by the increasing size of this population, of which inpatient care accounted for 47%. GLDs constituted the smallest share of costs. CVD was the most resource-requiring disease group. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s41669-017-0063-y) contains supplementary material, which is available to authorized users. Springer International Publishing 2017-11-27 /pmc/articles/PMC6249189/ /pubmed/29623637 http://dx.doi.org/10.1007/s41669-017-0063-y Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Research Article Nathanson, David Sabale, Ugne Eriksson, Jan W. Nyström, Thomas Norhammar, Anna Olsson, Urban Bodegård, Johan Healthcare Cost Development in a Type 2 Diabetes Patient Population on Glucose-Lowering Drug Treatment: A Nationwide Observational Study 2006–2014 |
title | Healthcare Cost Development in a Type 2 Diabetes Patient Population on Glucose-Lowering Drug Treatment: A Nationwide Observational Study 2006–2014 |
title_full | Healthcare Cost Development in a Type 2 Diabetes Patient Population on Glucose-Lowering Drug Treatment: A Nationwide Observational Study 2006–2014 |
title_fullStr | Healthcare Cost Development in a Type 2 Diabetes Patient Population on Glucose-Lowering Drug Treatment: A Nationwide Observational Study 2006–2014 |
title_full_unstemmed | Healthcare Cost Development in a Type 2 Diabetes Patient Population on Glucose-Lowering Drug Treatment: A Nationwide Observational Study 2006–2014 |
title_short | Healthcare Cost Development in a Type 2 Diabetes Patient Population on Glucose-Lowering Drug Treatment: A Nationwide Observational Study 2006–2014 |
title_sort | healthcare cost development in a type 2 diabetes patient population on glucose-lowering drug treatment: a nationwide observational study 2006–2014 |
topic | Original Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6249189/ https://www.ncbi.nlm.nih.gov/pubmed/29623637 http://dx.doi.org/10.1007/s41669-017-0063-y |
work_keys_str_mv | AT nathansondavid healthcarecostdevelopmentinatype2diabetespatientpopulationonglucoseloweringdrugtreatmentanationwideobservationalstudy20062014 AT sabaleugne healthcarecostdevelopmentinatype2diabetespatientpopulationonglucoseloweringdrugtreatmentanationwideobservationalstudy20062014 AT erikssonjanw healthcarecostdevelopmentinatype2diabetespatientpopulationonglucoseloweringdrugtreatmentanationwideobservationalstudy20062014 AT nystromthomas healthcarecostdevelopmentinatype2diabetespatientpopulationonglucoseloweringdrugtreatmentanationwideobservationalstudy20062014 AT norhammaranna healthcarecostdevelopmentinatype2diabetespatientpopulationonglucoseloweringdrugtreatmentanationwideobservationalstudy20062014 AT olssonurban healthcarecostdevelopmentinatype2diabetespatientpopulationonglucoseloweringdrugtreatmentanationwideobservationalstudy20062014 AT bodegardjohan healthcarecostdevelopmentinatype2diabetespatientpopulationonglucoseloweringdrugtreatmentanationwideobservationalstudy20062014 |